Inactive Instrument

News Abpro Corporation

Equities

US0008501076

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Abpro Corporation entered into a term sheet to acquire Atlantic Coastal Acquisition Corp. II from a group of shareholders for approximately $770 million in a reverse merger transaction.	23-09-20	CI
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of Cancer Treatment Bispecific Antibody	22-09-21	CI
Abpro Corporation announced that it expects to receive $79.999992 million in funding	22-03-29	CI
Abpro Corporation Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant	21-12-09	CI
Abpro Announces Positive Phase 1 Results Demonstrating a Favorable Safety and Pharmacokinetic Profile of ABP 300, a Neutralizing Antibody Therapeutic for the Treatment of COVID-19	21-02-02	CI
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19	20-12-16	CI
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19	20-10-20	CI
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets	20-03-03	GL
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets	20-03-03	CI
Abpro Corporation announced that it expects to receive $29.999984 million in funding from Abpro Bio International, Inc.	19-10-30	CI
Abpro and NJCTTQ Enters Into Partnership for Development of Multiple Novel Bispecific Antibodies	19-02-28	CI
Abpro Corporation has withdrawn its IPO in the amount of $64 million.	18-05-16	CI
Abpro Corporation has filed an IPO in the amount of $69 million.	18-04-11	CI
Abpro Seeks Acquisitions	18-04-11	CI
Abpro Corporation announced that it has received $9.99999 million in funding	17-04-06	CI
Abpro Corporation announced a financing transaction	17-03-30	CI
Abpro Appoints MacBeath as Chief Scientific Officer	17-03-21	CI
Abpro Announces Agreements with Massachusetts General Hospital and Brigham and Women's Hospital to Co-Develop Therapeutics for Inflammation, Autoimmunity, Fibrosis, Oncology	16-05-19	CI
Abpro Announces Investment and Partnership with Essex Bio for Development of Antibody Therapeutics	16-04-06	CI
Abpro Corporation announced that it has received $3.5 million in funding from Essex Bio-Technology Limited	16-04-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Abpro Corporation

Equities

US0008501076

Summary

Filters